Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease
NCT07919197Phase 1Not yet recruiting
- Sponsor
- Moderna Inc
- Start
- Nov 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mRNA-1469 in Ebola virus disease (EVD) (16 arms), sponsored by Moderna Inc. Primary endpoints: Number of Participants with Solicited Local and Systemic Adverse Reactions at Day 7, Number of Participants with Unsolicited Adverse Events at Day 28 and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
mRNA-1469
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT07919197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919197.